Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Other Non-Current Assets (2023 - 2025)

Zenas BioPharma has reported Other Non-Current Assets over the past 3 years, most recently at $13.8 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $13.8 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $13.8 million (changed N/A YoY), and the annual figure for FY2025 was $13.8 million, changed.
  • Other Non-Current Assets for Q4 2025 was $13.8 million at Zenas BioPharma, up from $12.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for ZBIO hit a ceiling of $13.8 million in Q4 2025 and a floor of $86000.0 in Q3 2023.
  • Median Other Non-Current Assets over the past 3 years was $7.3 million (2023), compared with a mean of $6.7 million.
  • Biggest five-year swings in Other Non-Current Assets: increased 3.49% in 2024 and later skyrocketed 14374.16% in 2025.
  • Zenas BioPharma's Other Non-Current Assets stood at $7.3 million in 2023, then plummeted by 98.78% to $89000.0 in 2024, then surged by 15415.73% to $13.8 million in 2025.
  • The last three reported values for Other Non-Current Assets were $13.8 million (Q4 2025), $12.9 million (Q3 2025), and $90000.0 (Q2 2025) per Business Quant data.